Additional file 2: Figure S2. of Alzheimer’s disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression

AAV-PS1 and AAV-APP mice do not exhibit neuronal defects in terms of PSD-95, GLT-1 and tonic glutamatergic current. C57Bl/6 J mice (all males) were injected at 8 weeks of age either with AAV-CAG-PS1M146L (AAV-PS1 mice) or AAV-CAG-APPSL (AAV-APP mice). Mice were killed three months later for analyses. (A) Western blot of PSD-95 and GLT-1 (n = 3-4 per group). (B) Densitometric analyses of the antibody immunoreactivities shown in panel A. (C) Tonic glutamatergic current recorded at a holding potential of +40 mV by the whole-cell patch-clamping of CA1 pyramidal cells. No significant difference in tonic glutamatergic current intensity was observed between the AAV-PS1 and AAV-APP groups (whole cell patch-clamp of CA1 pyramidal cells, n = 11/group from n = 10 mice per group). (PNG 447 kb